Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCRX | 8-K | neutral | 5/10 | BioCryst reported Q1 2026 ORLADEYO revenue of $148.3M (+11% y-o-y; +21% on a comparable ex-Europe basis), in line with t | May 6, 2026 |
| MDGL | 8-K | bullish | 7/10 | Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consensus revenue estimate | May 6, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals reported Q1 2026 EPS of -$0.21, beating consensus of -$0.26 by 18.3%, while revenue of $6.5M m | May 6, 2026 |
| ELAN | 8-K | bullish | 8/10 | Elanco reported Q1 2026 adjusted EPS of $0.40, beating the $0.34 consensus by 17.6%, on revenue of $1.371B (+15% YoY, +1 | May 6, 2026 |
| IPHYF | 6-K | neutral | 2/10 | Innate Pharma filed a 6-K announcing a Q1 2026 business update conference call scheduled for May 13, 2026. The filing co | May 6, 2026 |
| BEIGF | 8-K | bullish | 8/10 | BeOne Medicines reported Q1 2026 total revenue of $1.51B, a 35% YoY increase, driven by BRUKINSA global sales of $1.1B ( | May 6, 2026 |
| VRDN | 424B5 | mixed | 7/10 | Viridian Therapeutics is conducting a $250M dual-tranche capital raise, a $100M equity offering (common stock + Series B | May 6, 2026 |
| AVTX | PRESS-RELEASE | bearish | 7/10 | Avalo Therapeutics priced a $375M underwritten public offering of 19.73M shares at $17.75/share plus pre-funded warrants | May 5, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-day window, with the C | May 5, 2026 |
| TVTX | 144 | neutral | 2/10 | Elizabeth E. Reed, an officer of Travere Therapeutics, filed a Form 144 to sell 2,174 shares for approximately $101,417 | May 5, 2026 |
| ACAD | CLUSTER | neutral | 2/10 | Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~$105K on May 4, 2026 | May 5, 2026 |
| IDYA | 8-K | neutral | 2/10 | IDEAYA Biosciences filed a new automatic shelf registration statement (Form S-3ASR) to replace its prior shelf that was | May 5, 2026 |
| AURA | 8-K | bearish | 7/10 | Aura Biosciences priced a massive underwritten public offering of 46.1M shares of common stock and pre-funded warrants f | May 5, 2026 |
| IDYA | 424B5 | mixed | 5/10 | IDEAYA Biosciences filed a prospectus supplement on May 5, 2026, for an at-the-market (ATM) offering of up to $156.6 mil | May 5, 2026 |
| AURA | PRESS-RELEASE | bearish | 7/10 | Aura Biosciences closed an underwritten public offering of 46.1M shares and 3.8M pre-funded warrants at $6.00 per share, | May 5, 2026 |
| HYPD | DEFA14A | neutral | 3/10 | Hyperion DeFi filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting to be held virtually on | May 5, 2026 |
| PURE | 8-K | bearish | 5/10 | Pure Bioscience raised $1.0 million via a private placement, issuing 18,131,096 shares at $0.0553 per share (20% discoun | May 5, 2026 |
| CLNN | 424B5 | bearish | 7/10 | Clene Inc. is offering 1,000,000 shares of common stock at $7.00 per share, a 13.5% discount to the $8.09 closing price | May 5, 2026 |
| SCNX | 8-K | neutral | 2/10 | Scienture Holdings posted a revised investor presentation to its website on May 5, 2026, for use in meetings with analys | May 5, 2026 |
| SRZN | CLUSTER | neutral | 2/10 | CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val | May 5, 2026 |
| KNSA | CLUSTER | neutral | 4/10 | Kiniksa Pharmaceuticals insiders, including CEO and CMO, sold $5.28M in shares during the week following strong Q1 2026 | May 5, 2026 |
| PAHC | 8-K | neutral | 2/10 | Phibro Animal Health Corp declared a quarterly cash dividend of $0.12 per share, payable June 24, 2026, to shareholders | May 5, 2026 |
| CYTK | 424B5 | mixed | 6/10 | Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritten by Morgan Stanley | May 5, 2026 |
| CHRS | DEFA14A | neutral | 2/10 | Coherus Oncology filed definitive additional proxy materials (DEFA14A) reminding employees to vote at the May 27, 2026 a | May 5, 2026 |
| NUVL | CLUSTER | neutral | 2/10 | Three Nuvalent insiders (CFO, CLO, CDO) sold a total of ~$1.27M in open-market shares over three days, with all sales ti | May 5, 2026 |
| INMB | 8-K | neutral | 4/10 | Inmune Bio entered into an amended and restated Material Transfer and License Agreement with Anthony Nolan, securing lon | May 5, 2026 |
| AVTX | 424B5 | mixed | 6/10 | Avalo Therapeutics filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre | May 5, 2026 |
| OTLC | 8-K | neutral | 5/10 | Oncotelic Therapeutics completed a multi-step transaction (May 1, 2026) contributing its patent portfolio to Lunai Biowo | May 5, 2026 |
| CYTK | CLUSTER | mixed | 4/10 | Multiple CYTK insiders, including CFO and CCO, sold shares totaling $4.53M on the same day as Q1 2026 earnings release s | May 5, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two insiders at Cytokinetics sold a combined $2.39M in open-market stock on May 5, 2026, the same day the company report | May 5, 2026 |